Future recommendations involve conducting the dose–response curve for the PDL-1 inhibitor, measuring MSLN and CD80 on the protein level, and examining the interlinkage between MALAT1 and CTLA4 in TAMs of BC. This evidence concerns the gene CD80 and breast cancer.